New Approaches to the Management of Gram-Negative Resistant Infections

By attending these interactive 1-hour live dinner meetings, you will:

  • Gain important insights on the appropriate use of standard and novel antibiotics in the battle against MDR Gram-negative infections
  • Engage with national and local infectious disease experts as they discuss the growing carbapenem-resistant Enterobacteriaceae (CRE) threat to hospitalized patients
  • Apply these learnings to develop infection management protocols for MDR Gram-negative infections that optimize patient outcomes and support antimicrobial stewardship


6:30 PM - 7:00 PM Registration and Dinner
7:00 PM - 8:00 PM Program

  • Gram-Negative Bacteria: Overview/Review
  • New Approaches to the Treatment of MDR Gram-Negative Infections
    • Novel compounds and combinations
    • Emerging testing and monitoring strategies
  • Audience Question and Answer Session


Date / Time
Event Details
6:30 PM
6:30 PM
6:30 PM
6:30 PM
6:30 PM

New Approaches to the Management of Gram-Negative Resistant Infections

Jacksonville, FL
Maggiano's Little Italy - Jacksonville Details


Program Director
Robert A. Bonomo, MD

Case Western Reserve University
Cleveland Veterans Affairs Medical Center
Cleveland, Ohio

Program Director
Keith Kaye, MD, MPH

Division of Infectious Diseases
Department of Internal Medicine
University of Michigan Medical School
University of Michigan Health System
Ann Arbor, Michigan

Lilian Abbo, MD

Associate Professor of Clinical Infectious Diseases
Division of Infectious Diseases
Department of Medicine
University of Miami Miller School of Medicine
Chief, Infection Control and Antimicrobial Stewardship
Jackson Health System
University of Miami
Miami, Florida

Michael Bolaris, MD

David Geffen School of Medicine at UCLA
Harbor-UCLA Medical Center
Torrance, California

Yohei Doi, MD, PhD

Associate Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh School of Medicine
Infectious Diseases Specialist
Division of Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Spencer Durham, PharmD

Auburn University Harrison School of Pharmacy
Auburn, Alabama

Debra Goff, PharmD, FCCP

Associate Professor
College of Pharmacy
The Ohio State University
Infectious Diseases Specialist
Department of Pharmacy
The Ohio State University Wexner Medical Center
Columbus, Ohio

Christopher Jankowski, PharmD

University of Florida Health Jacksonville,
Jacksonville, Florida

George H. Karam, MD

Paula Garvey Manship Chair of Medicine
Department of Medicine
LSU School of Medicine
New Orleans, Louisiana

William R. Miller, MD

Assistant Professor
Division of Infectious Diseases
UTHealth McGovern Medical School
Houston, Texas

Jason Pogue, MD

Sinai Grace Hospital
Detroit Medical Center
Detroit, Michigan

Michael Satlin, MD

Weill Cornell Medicine
New York, New York

Jose Vazquez, MD

Chief, Division of Infectious Diseases
Professor of Medicine
Department of Medicine
Medical College of Georgia/Augusta University
Augusta, Georgia

Marcus J. Zervos, MD

Wayne State University
Henry Ford Hospital
Detroit, Michigan


The goal of this activity is to improve participants’ knowledge and competence in applying current and emerging antibacterials in the management of patients with resistant Gram-negative infections.

Target Audience
This program is intended for physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other healthcare providers who care for patients with multidrug-resistant Gram-negative infections.

Learning Objectives

  • Review the epidemiology and changing patterns of multidrug resistance of Gram-negative bacteria to include local trends and the significance of this information in clinical practice
  • Explore key clinical trial data on new and emerging therapeutic options against multidrug-resistant Gram-negative bacteria, with attention to safety, efficacy, and adverse event profiles of newer agents vs those of established agents of the same class
  • Discuss individualized management approaches to the treatment of multidrug-resistant Gram-negative infections with a focus on next-generation antimicrobial agents and their potential utility for reducing resistance and improving patient-specific administration and dosing considerations


Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Medical Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

A statement of credit will be issued only upon completion of the online activity evaluation form.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours.

Pharmacist Continuing Medical Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-118-L01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.